

Resource Summary Report

Generated by RRID on Sep 9, 2026

Cyclin E1 (D7T3U)

RRID:AB_2783554

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 20808, RRID:AB_2783554

Antibody Information

URL: http://antibodyregistry.org/AB_2783554

Proper Citation: Cell Signaling Technology Cat# 20808, RRID:AB_2783554

Target Antigen: Cyclin E1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: Cyclin E1 (D7T3U)

Description: This monoclonal targets Cyclin E1

Target Organism: rat, mouse, human

Clone ID: D7T3U

Antibody ID: AB_2783554

Vendor: Cell Signaling Technology

Catalog Number: 20808

Record Creation Time: 20231110T032958+0000

Record Last Update: 20260829T083538+0000

Ratings and Alerts

No rating or validation information has been found for Cyclin E1 (D7T3U).

No alerts have been found for Cyclin E1 (D7T3U).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. *Oncogene*, 45(28), 2823.

Sethi SC, et al. (2025) Chromatin remodeling activity of EP400 safeguards chromosomal stability by preventing CENP-A mislocalization. *Cell reports*, 44(11), 116423.

Li X, et al. (2025) SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer. *Journal of ovarian research*, 18(1), 167.

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. *Molecular cancer therapeutics*, 24(8), 1265.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Guo Y, et al. (2025) Novel compounds with promising HuH-7 inhibitory activity as new cancer drug candidates: derivatives of N,N'-diphenylurea linked with 1,2,3-triazole. *Journal of enzyme inhibition and medicinal chemistry*, 40(1), 2585597.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. *Cell reports. Medicine*, 6(5), 102133.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Wang Z, et al. (2024) UA influences the progression of breast cancer via the AhR/p27Kip1/cyclin E pathway. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 38(18), e70058.

Goto Y, et al. (2024) A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. *Cancer research communications*, 4(7), 1850.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. *Cell*, 187(7), 1666.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. *bioRxiv : the preprint server for biology*.

Abdelrahim M, et al. (2024) Light-mediated intracellular polymerization. *Nature protocols*.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. *Molecular cancer therapeutics*, 23(10), 1494.

Takashima S, et al. (2024) Alternative mRNA splicing events and regulators in epidermal differentiation. *Cell reports*, 43(3), 113814.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. *Cancer discovery*, 14(3), 446.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. *iScience*, 27(7), 109978.

Yang J, et al. (2024) Mecp2 fine-tunes quiescence exit by targeting nuclear receptors. *eLife*, 12.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.